PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31704822-1	2019	BACKGROUND/AIM: Lenvatinib is a potent inhibitor of receptor tyrosine kinases, targeting vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), KIT, and RET.	lenvatinib	16-26	FMS-like tyrosine kinase 1	Mus musculus	135-141	
28901423-3	2017	Lenvatinib is a multi-targeted anticancer agent that targets of receptor tyrosine kinases including vascular endothelial growth factor receptor 1 and 2, fibroblast growth factor receptor 1, platelet-derived growth factor receptor beta and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog.	lenvatinib	0-10	FMS-like tyrosine kinase 1	Mus musculus	100-151	
29201215-5	2017	The TNCA used was lenvatinib, a multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor beta, proto-oncogene tyrosine-protein kinase receptor Ret and mast/stem cell growth factor receptor Kit.	lenvatinib	18-28	FMS-like tyrosine kinase 1	Mus musculus	85-132